Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2174 entries
Sorted by: Best Match Show Resources per page
Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study.

Journal of personalized medicine

Fu MR, Axelrod D, Guth AA, Fletcher J, Qiu JM, Scagliola J, Kleinman R, Ryan CE, Chan N, Haber J.
PMID: 26404383
J Pers Med. 2015 Sep 03;5(3):326-40. doi: 10.3390/jpm5030326.

Obesity is one of the risk factors for developing lymphedema following breast cancer treatment. We prospectively enrolled 140 women and followed the participants for 12 months after surgery to investigate patterns of obesity and lymph fluid level in the...

Cite
Fu MR, Axelrod D, Guth AA, et al. Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study. J Pers Med. 2015;5(3):326-40doi: 10.3390/jpm5030326.
Fu, M. R., Axelrod, D., Guth, A. A., Fletcher, J., Qiu, J. M., Scagliola, J., Kleinman, R., Ryan, C. E., Chan, N., & Haber, J. (2015). Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study. Journal of personalized medicine, 5(3), 326-40. https://doi.org/10.3390/jpm5030326
Fu, Mei R, et al. "Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study." Journal of personalized medicine vol. 5,3 (2015): 326-40. doi: https://doi.org/10.3390/jpm5030326
Fu MR, Axelrod D, Guth AA, Fletcher J, Qiu JM, Scagliola J, Kleinman R, Ryan CE, Chan N, Haber J. Patterns of Obesity and Lymph Fluid Level during the First Year of Breast Cancer Treatment: A Prospective Study. J Pers Med. 2015 Sep 03;5(3):326-40. doi: 10.3390/jpm5030326. PMID: 26404383; PMCID: PMC4600151.
Copy Download .nbib Format: NLM
Prospective Lymphedema Surveillance in a Clinic Setting.

Journal of personalized medicine

Chance-Hetzler J, Armer J, Van Loo M, Anderson B, Harris R, Ewing R, Stewart B.
PMID: 26308061
J Pers Med. 2015 Aug 25;5(3):311-25. doi: 10.3390/jpm5030311.

The potential impact of breast cancer-related lymphedema (LE) is quite extensive, yet it often remains under-diagnosed until the later stages. This project examines the effectiveness of prospective surveillance in post-surgical breast cancer patients. A retrospective analysis of 49 out...

Cite
Chance-Hetzler J, Armer J, Van Loo M, et al. Prospective Lymphedema Surveillance in a Clinic Setting. J Pers Med. 2015;5(3):311-25doi: 10.3390/jpm5030311.
Chance-Hetzler, J., Armer, J., Van Loo, M., Anderson, B., Harris, R., Ewing, R., & Stewart, B. (2015). Prospective Lymphedema Surveillance in a Clinic Setting. Journal of personalized medicine, 5(3), 311-25. https://doi.org/10.3390/jpm5030311
Chance-Hetzler, Janet, et al. "Prospective Lymphedema Surveillance in a Clinic Setting." Journal of personalized medicine vol. 5,3 (2015): 311-25. doi: https://doi.org/10.3390/jpm5030311
Chance-Hetzler J, Armer J, Van Loo M, Anderson B, Harris R, Ewing R, Stewart B. Prospective Lymphedema Surveillance in a Clinic Setting. J Pers Med. 2015 Aug 25;5(3):311-25. doi: 10.3390/jpm5030311. PMID: 26308061; PMCID: PMC4600150.
Copy Download .nbib Format: NLM
Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation.

Journal of personalized medicine

Vallée Marcotte B, Cormier H, Rudkowska I, Lemieux S, Couture P, Vohl MC.
PMID: 29113108
J Pers Med. 2017 Nov 06;7(4). doi: 10.3390/jpm7040015.

The objective was to test whether

Cite
Vallée Marcotte B, Cormier H, Rudkowska I, et al. Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation. J Pers Med. 2017;7(4)doi: 10.3390/jpm7040015.
Vallée Marcotte, B., Cormier, H., Rudkowska, I., Lemieux, S., Couture, P., & Vohl, M. C. (2017). Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation. Journal of personalized medicine, 7(4), . https://doi.org/10.3390/jpm7040015
Vallée Marcotte, Bastien, et al. "Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation." Journal of personalized medicine vol. 7,4 (2017). doi: https://doi.org/10.3390/jpm7040015
Vallée Marcotte B, Cormier H, Rudkowska I, Lemieux S, Couture P, Vohl MC. Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation. J Pers Med. 2017 Nov 06;7(4). doi: 10.3390/jpm7040015. PMID: 29113108; PMCID: PMC5748627.
Copy Download .nbib Format: NLM
The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer.

Journal of personalized medicine

Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O.
PMID: 28657610
J Pers Med. 2017 Jun 28;7(3). doi: 10.3390/jpm7030005.

Advances in personalized medicine are supported by companion diagnostic molecular tests. Testing accuracy is critical for selecting patients for optimal therapy and reducing treatment-related toxicity. We assessed the clinical and economic impact of inaccurate test results between laboratory developed...

Cite
Cheng MM, Palma JF, Scudder S, et al. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. J Pers Med. 2017;7(3)doi: 10.3390/jpm7030005.
Cheng, M. M., Palma, J. F., Scudder, S., Poulios, N., & Liesenfeld, O. (2017). The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. Journal of personalized medicine, 7(3), . https://doi.org/10.3390/jpm7030005
Cheng, Mindy M, et al. "The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer." Journal of personalized medicine vol. 7,3 (2017). doi: https://doi.org/10.3390/jpm7030005
Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. J Pers Med. 2017 Jun 28;7(3). doi: 10.3390/jpm7030005. PMID: 28657610; PMCID: PMC5618152.
Copy Download .nbib Format: NLM
Tailoring Nutritional Advice for Mexicans Based on Prevalence Profiles of Diet-Related Adaptive Gene Polymorphisms.

Journal of personalized medicine

Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, Sepulveda-Villegas M, Rivera-Iñiguez I, Roman S.
PMID: 29125573
J Pers Med. 2017 Nov 10;7(4). doi: 10.3390/jpm7040016.

Diet-related adaptive gene (DRAG) polymorphisms identified in specific populations are associated with chronic disorders in carriers of the adaptive alleles due to changes in dietary and lifestyle patterns in recent times. Mexico's population is comprised of Amerindians (AM) and...

Cite
Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, et al. Tailoring Nutritional Advice for Mexicans Based on Prevalence Profiles of Diet-Related Adaptive Gene Polymorphisms. J Pers Med. 2017;7(4)doi: 10.3390/jpm7040016.
Ojeda-Granados, C., Panduro, A., Gonzalez-Aldaco, K., Sepulveda-Villegas, M., Rivera-Iñiguez, I., & Roman, S. (2017). Tailoring Nutritional Advice for Mexicans Based on Prevalence Profiles of Diet-Related Adaptive Gene Polymorphisms. Journal of personalized medicine, 7(4), . https://doi.org/10.3390/jpm7040016
Ojeda-Granados, Claudia, et al. "Tailoring Nutritional Advice for Mexicans Based on Prevalence Profiles of Diet-Related Adaptive Gene Polymorphisms." Journal of personalized medicine vol. 7,4 (2017). doi: https://doi.org/10.3390/jpm7040016
Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, Sepulveda-Villegas M, Rivera-Iñiguez I, Roman S. Tailoring Nutritional Advice for Mexicans Based on Prevalence Profiles of Diet-Related Adaptive Gene Polymorphisms. J Pers Med. 2017 Nov 10;7(4). doi: 10.3390/jpm7040016. PMID: 29125573; PMCID: PMC5748628.
Copy Download .nbib Format: NLM
Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.

Journal of personalized medicine

Aka I, Bernal CJ, Carroll R, Maxwell-Horn A, Oshikoya KA, Van Driest SL.
PMID: 29099060
J Pers Med. 2017 Nov 02;7(4). doi: 10.3390/jpm7040014.

Cytochrome P450 (CYP) enzymes are commonly involved in drug metabolism, and genetic variation in the genes encoding CYPs are associated with variable drug response. While genotype-guided therapy has been clinically implemented in adults, these associations are less well established...

Cite
Aka I, Bernal CJ, Carroll R, et al. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017;7(4)doi: 10.3390/jpm7040014.
Aka, I., Bernal, C. J., Carroll, R., Maxwell-Horn, A., Oshikoya, K. A., & Van Driest, S. L. (2017). Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. Journal of personalized medicine, 7(4), . https://doi.org/10.3390/jpm7040014
Aka, Ida, et al. "Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children." Journal of personalized medicine vol. 7,4 (2017). doi: https://doi.org/10.3390/jpm7040014
Aka I, Bernal CJ, Carroll R, Maxwell-Horn A, Oshikoya KA, Van Driest SL. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med. 2017 Nov 02;7(4). doi: 10.3390/jpm7040014. PMID: 29099060; PMCID: PMC5748626.
Copy Download .nbib Format: NLM
Rapid collection of biospecimens by automated identification of patients eligible for pharmacoepigenetic studies.

Journal of personalized medicine

Sun YV, Davis RL.
PMID: 25562727
J Pers Med. 2013 Sep 26;3(4):263-74. doi: 10.3390/jpm3040263.

Epigenetics plays an important role in regulating gene expression, and can be modified by environmental factors and physiological conditions. Studying epigenetics is a promising approach to potentially improving the diagnosis, prevention and treatment of human diseases, and to providing...

Cite
Sun YV, Davis RL. Rapid collection of biospecimens by automated identification of patients eligible for pharmacoepigenetic studies. J Pers Med. 2013;3(4):263-74doi: 10.3390/jpm3040263.
Sun, Y. V., & Davis, R. L. (2013). Rapid collection of biospecimens by automated identification of patients eligible for pharmacoepigenetic studies. Journal of personalized medicine, 3(4), 263-74. https://doi.org/10.3390/jpm3040263
Sun, Yan V, and Davis, Robert L. "Rapid collection of biospecimens by automated identification of patients eligible for pharmacoepigenetic studies." Journal of personalized medicine vol. 3,4 (2013): 263-74. doi: https://doi.org/10.3390/jpm3040263
Sun YV, Davis RL. Rapid collection of biospecimens by automated identification of patients eligible for pharmacoepigenetic studies. J Pers Med. 2013 Sep 26;3(4):263-74. doi: 10.3390/jpm3040263. PMID: 25562727; PMCID: PMC4251387.
Copy Download .nbib Format: NLM
Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.

Journal of personalized medicine

Kelleher FC, Solomon B, McArthur GA.
PMID: 25562798
J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035.

The incorporation of individualized molecular therapeutics into routine clinical practice for both non-small cell lung cancer (NSCLC) and melanoma are amongst the most significant advances of the last decades in medical oncology. In NSCLC activating somatic mutations in exons...

Cite
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med. 2012;2(2):35-49doi: 10.3390/jpm2020035.
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012). Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. Journal of personalized medicine, 2(2), 35-49. https://doi.org/10.3390/jpm2020035
Kelleher, Fergal C, et al. "Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer." Journal of personalized medicine vol. 2,2 (2012): 35-49. doi: https://doi.org/10.3390/jpm2020035
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035. PMID: 25562798; PMCID: PMC4251364.
Copy Download .nbib Format: NLM
Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies.

Journal of personalized medicine

Bissonnette L, Bergeron MG.
PMID: 25562799
J Pers Med. 2012 May 02;2(2):50-70. doi: 10.3390/jpm2020050.

Infectious disease management essentially consists in identifying the microbial cause(s) of an infection, initiating if necessary antimicrobial therapy against microbes, and controlling host reactions to infection. In clinical microbiology, the turnaround time of the diagnostic cycle (>24 hours) often...

Cite
Bissonnette L, Bergeron MG. Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies. J Pers Med. 2012;2(2):50-70doi: 10.3390/jpm2020050.
Bissonnette, L., & Bergeron, M. G. (2012). Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies. Journal of personalized medicine, 2(2), 50-70. https://doi.org/10.3390/jpm2020050
Bissonnette, Luc, and Bergeron, Michel G. "Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies." Journal of personalized medicine vol. 2,2 (2012): 50-70. doi: https://doi.org/10.3390/jpm2020050
Bissonnette L, Bergeron MG. Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies. J Pers Med. 2012 May 02;2(2):50-70. doi: 10.3390/jpm2020050. PMID: 25562799; PMCID: PMC4251365.
Copy Download .nbib Format: NLM
Formative evaluation of clinician experience with integrating family history-based clinical decision support into clinical practice.

Journal of personalized medicine

Doerr M, Edelman E, Gabitzsch E, Eng C, Teng K.
PMID: 25563219
J Pers Med. 2014 Mar 26;4(2):115-36. doi: 10.3390/jpm4020115.

Family health history is a leading predictor of disease risk. Nonetheless, it is underutilized to guide care and, therefore, is ripe for health information technology intervention. To fill the family health history practice gap, Cleveland Clinic has developed a...

Cite
Doerr M, Edelman E, Gabitzsch E, et al. Formative evaluation of clinician experience with integrating family history-based clinical decision support into clinical practice. J Pers Med. 2014;4(2):115-36doi: 10.3390/jpm4020115.
Doerr, M., Edelman, E., Gabitzsch, E., Eng, C., & Teng, K. (2014). Formative evaluation of clinician experience with integrating family history-based clinical decision support into clinical practice. Journal of personalized medicine, 4(2), 115-36. https://doi.org/10.3390/jpm4020115
Doerr, Megan, et al. "Formative evaluation of clinician experience with integrating family history-based clinical decision support into clinical practice." Journal of personalized medicine vol. 4,2 (2014): 115-36. doi: https://doi.org/10.3390/jpm4020115
Doerr M, Edelman E, Gabitzsch E, Eng C, Teng K. Formative evaluation of clinician experience with integrating family history-based clinical decision support into clinical practice. J Pers Med. 2014 Mar 26;4(2):115-36. doi: 10.3390/jpm4020115. PMID: 25563219; PMCID: PMC4263968.
Copy Download .nbib Format: NLM
Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement.

Journal of personalized medicine

Cohen JP, Felix AE.
PMID: 25563222
J Pers Med. 2014 Apr 04;4(2):163-75. doi: 10.3390/jpm4020163.

BACKGROUND: Personalized medicine is gradually emerging as a transformative field. Thus far, seven co-developed drug-diagnostic combinations have been approved and several dozen post-hoc drug-diagnostic combinations (diagnostic approved after the drug). However, barriers remain, particularly with respect to reimbursement. Purpose,...

Cite
Cohen JP, Felix AE. Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. J Pers Med. 2014;4(2):163-75doi: 10.3390/jpm4020163.
Cohen, J. P., & Felix, A. E. (2014). Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. Journal of personalized medicine, 4(2), 163-75. https://doi.org/10.3390/jpm4020163
Cohen, Joshua P, and Felix, Abigail E. "Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement." Journal of personalized medicine vol. 4,2 (2014): 163-75. doi: https://doi.org/10.3390/jpm4020163
Cohen JP, Felix AE. Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement. J Pers Med. 2014 Apr 04;4(2):163-75. doi: 10.3390/jpm4020163. PMID: 25563222; PMCID: PMC4263971.
Copy Download .nbib Format: NLM
Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy.

Journal of personalized medicine

Morales M, Ávila J, González-Fernández R, Boronat L, Soriano ML, Martín-Vasallo P.
PMID: 25563226
J Pers Med. 2014 Jun 05;4(2):282-96. doi: 10.3390/jpm4020282.

Anticancer chemotherapy (CT) produces non-desirable effects on normal healthy cells and tissues. Oxaliplatin is widely used in the treatment of colorectal cancer and responsible for the development of sensory neuropathy in varying degrees, from complete tolerance to chronic neuropathic...

Cite
Morales M, Ávila J, González-Fernández R, et al. Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. J Pers Med. 2014;4(2):282-96doi: 10.3390/jpm4020282.
Morales, M., Ávila, J., González-Fernández, R., Boronat, L., Soriano, M. L., & Martín-Vasallo, P. (2014). Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. Journal of personalized medicine, 4(2), 282-96. https://doi.org/10.3390/jpm4020282
Morales, Manuel, et al. "Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy." Journal of personalized medicine vol. 4,2 (2014): 282-96. doi: https://doi.org/10.3390/jpm4020282
Morales M, Ávila J, González-Fernández R, Boronat L, Soriano ML, Martín-Vasallo P. Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy. J Pers Med. 2014 Jun 05;4(2):282-96. doi: 10.3390/jpm4020282. PMID: 25563226; PMCID: PMC4263976.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2174 entries